News | 24 December 2025
Niagen Bioscience secures full ownership of key NAD+ patents in major IP move
The portfolio includes foundational patents on the production, composition, and commercial use of NR
The portfolio includes foundational patents on the production, composition, and commercial use of NR
If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
NUFYMCO BLA has been approved by the USFDA
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the facility
The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
The initiative is focused on a problem that continues to plague cancer outcomes in India
The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club
The pharma company will donate more than seven tons of its active pharmaceutical ingredient (API) to bolster the American supply chain
Subscribe To Our Newsletter & Stay Updated
